Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Short term Debt (2019 - 2020)

Ovid Therapeutics filings provide 2 years of Short term Debt readings, the most recent being $2.4 million for Q4 2020.

  • Quarterly Short term Debt rose 21845.5% to $2.4 million in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $2.4 million through Dec 2020, up 21845.5% year-over-year, with the annual reading at $2.4 million for FY2020, 21845.5% up from the prior year.
  • Short term Debt hit $2.4 million in Q4 2020 for Ovid Therapeutics, up from $226536.0 in the prior quarter.
  • Across five years, Short term Debt topped out at $2.4 million in Q4 2020 and bottomed at $10804.0 in Q4 2019.